1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway

Carcinogenesis

Volumn 32, Issue 6, 2011, Pages 904-912

  Pang, Xiufeng ^a   Zhang, Li ^a   Lai, Li ^a   Chen, Jing ^a   Wu, Yuanyuan ^a   Yi, Zhengfang ^a   Zhang, Jian ^b   Qu, Weijing ^a   Aggarwal, Bharat B ^c   Liu, Mingyao ^a,d  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1' ACETOXYCHAVICOL ACETATE; ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; RAT; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; VASCULAR RING;

EID: 79958221484     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr052     Document Type: Article

References (47)

1. Folkman,J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285, 1182-1186.
2. Christofori,G. (2006) New signals from the invasive front. Nature, 441, 444-450.
3. Weidner,N. et al. (1996) Tumoral vascularity as a prognostic factor in cancer. Important Adv. Oncol., 167-190.
4. Summy,J.M. et al. (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev., 22, 337-358.
5. Schenone,S. et al. (2007) SRC inhibitors and angiogenesis. Curr. Pharm. Des., 13, 2118-2128.
6. Bolos,V. et al. (2010) The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther., 3, 83-97.
7. Wheeler,D.L. et al. (2009) The role of Src in solid tumors. Oncologist, 14, 667-678.
8. Eliceiri,B.P. et al. (2002) Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J. Cell Biol., 157, 149-160.
9. Trevino,J.G. et al. (2005) Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res., 65, 7214-7222.
10. Kim,L.C. et al. (2009) Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol., 6, 587-595.
11. Wei,J. et al. (2008) Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res., 28, 327-334.
12. Aragon-Ching,J.B. et al. (2009) VEGF inhibitors and prostate cancer therapy. Curr. Mol. Pharmacol., 2, 161-168.
13. Cook,K.M. et al. (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin., 60, 222-243.
14. Newman,D.J. et al. (2003) Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 66, 1022-1037.
15. Ichikawa,H. et al. (2006) 1'-Acetoxychavicol acetate inhibits RANKLinduced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation. Mol. Cancer Res., 4, 275-281.
16. Ye,Y. et al. (2006) 1'S-1'-acetoxychavicol acetate isolated from Alpinia galanga inhibits human immunodeficiency virus type 1 replication by blocking Rev transport. J. Gen. Virol., 87, 2047-2053.
17. Tamura,S. et al. (2010) Halogenated analogs of 1'-acetoxychavicol acetate, Rev-export inhibitor from Alpinia galanga, designed from mechanism of action. Bioorg. Med. Chem. Lett., 20, 2082-2085.
18. Ohnishi,M. et al. (1996) Chemopreventive effect of a xanthine oxidase inhibitor, 1'-acetoxychavicol acetate, on rat oral carcinogenesis. Jpn. J. Cancer Res., 87, 349-356.
19. Murakami,A. et al. (1996) 1'-Acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin. Oncology, 53, 386-391.
20. Ohata,T. et al. (1998) Inhibition by 1'-acetoxychavicol acetate of lipopolysaccharide-and interferon-gamma-induced nitric oxide production through suppression of inducible nitric oxide synthase gene expression in RAW264 cells. Carcinogenesis, 19, 1007-1012.
21. Tanaka,T. et al. (1997) Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor, 1'-acetoxychavicol acetate. Jpn. J. Cancer Res., 88, 821-830.
22. Kawabata,K. et al. (2000) Suppression of N-nitrosomethylbenzylamineinduced rat esophageal tumorigenesis by dietary feeding of 1'-acetoxychavicol acetate. Jpn. J. Cancer Res., 91, 148-155.
23. Ito,K. et al. (2004) Induction of apoptosis in human myeloid leukemic cells by 1'-acetoxychavicol acetate through a mitochondrial- and Fas-mediated dual mechanism. Clin. Cancer Res., 10, 2120-2130.
24. Moffatt,J. et al. (2002) Involvement of protein tyrosine phosphorylation and reduction of cellular sulfhydryl groups in cell death induced by 1' -acetoxychavicol acetate in Ehrlich ascites tumor cells. Chem. Biol. Interact., 139, 215-230.
25. Ito,K. et al. (2005) 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res., 65, 4417-4424.
26. Ichikawa,H. et al. (2005) Identification of a novel blocker of I kappa B alpha kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kappa B-regulated gene products. J. Immunol., 174, 7383-7392.
27. Pang,X. et al. (2009) Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res., 69, 518-525.
28. Pang,X. et al. (2010) Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate, a derivative of glycyrrhetinic acid, functions as a potent angiogenesis inhibitor. J. Pharmacol. Exp. Ther., 335, 172-179.
29. Alghisi,G.C. et al. (2009) The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One, 4, e4449.
30. Pang,X. et al. (2009) Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res., 69, 5893-5900.
31. Pang,X. et al. (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res., 70, 1951-1959.
32. Pyun,B.J. et al. (2008) Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity. Cancer Res., 68, 227-235.
33. Hennequin,L.F. et al. (2006) N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5 - (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem., 49, 6465-6488.
34. Mashimo,T. et al. (2000) Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes. Biochem. Biophys. Res. Commun., 274, 370-376.
35. Hanahan,D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
36. Hynes,R.O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell, 110, 673-687.
37. Patan,S. (2004) Vasculogenesis and angiogenesis. Cancer Treat. Res., 117, 3-32.
38. Taraboletti,G. et al. (2004) Modelling approaches for angiogenesis. Eur. J. Cancer, 40, 881-889.
39. Timpson,P. et al. (2001) Coordination of cell polarization and migration by the Rho family GTPases requires Src tyrosine kinase activity. Curr. Biol., 11, 1836-1846.
40. Neufeld,G. et al. (2006) Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev., 25, 373-385.
41. Schlessinger,J. (2000) New roles for Src kinases in control of cell survival and angiogenesis. Cell, 100, 293-296.
42. Chou,M.T. et al. (2002) Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem., 3, 32.
43. Clark,E.A. et al. (1998) Integrin-mediated signals regulated by members of the rho family of GTPases. J. Cell Biol., 142, 573-586.
44. Hanahan,D. et al. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
45. Kanda,S. et al. (2007) Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review). Int. J. Mol. Med., 20, 113-121.
46. Yao,H. et al. (2010) Molecular mechanisms involving sigma receptormediated induction of MCP-1: implication for increased monocyte transmigration. Blood, 115, 4951-4962.
47. Madhusudan,S. et al. (2002) Drug inhibition of angiogenesis. Curr. Opin. Pharmacol., 2, 403-414.